I do not believe the other companies with their GBM trials would be motivated to share their trial data. As we can see from ECA data shown in the JAMA article, the DCVax-L trial data beat the other trial’s data, so it likely would NOT have weakened the NWBO trial results.
Additionally, does anyone really think Linda Powers would be willing to share the DCVax-L P3 patient level data with a competitor?
Market Data 
Markets 
AI
